Merck Serono, a division of Merck KGaA, has launched Glucophage Powder for Oral Solution in Sachets, indicated for the first-line treatment of type 2 diabetes mellitus, in France and the UK. Marketing authorizations in other European countries for the new formulation of Glucophage are expected in the coming months. The new powder formulation is bioequivalent to the existing Glucophage tablets and is packaged in individual sachets of 500mg, 850mg and 1000mg. Glucophage powder dissolves in wate...